Abstract
The proto-oncogene c-myc has been shown to play a pivotal role in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis, and participates in regulating hematopoietic homeostasis. It is a transcription regulator that is part of an extensive network of interacting factors. Most probably, different biological responses are elicited by different overlapping subsets of c-Myc target genes, both induced and suppressed. Results obtained from studies employing mouse models are consistent with the need for at least one, and possibly two, mutations in addition to deregulated c-myc for malignant tumor formation. Repression of c-myc is required for terminal differentiation of many cell types, including hematopoietic cells. It has been shown that deregulated expression of c-myc in both M1 myeloid leukemic cells and normal myeloid cells derived from murine bone marrow, not only blocked terminal differentiation and its associated growth arrest, but also induced apoptosis, which is dependent on the Fas/CD95 pathway. There is evidence to suggest that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal myeloid differentiation program, and that deregulated c-myc expression can activate this signaling pathway prematurely. The ability of egr-1 to promote terminal myeloid differentiation when co-expressed with c-myc, and of c-fos to partially abrogate the block imparted by deregulated c-myc on myeloid differentiation, make these two genes candidate tumor suppressors. Several different transcription factors have been implicated in the down-regulation of c-myc expression during differentiation, including C/EBPα, CTCF, BLIMP-1, and RFX1. Alterations in the expression and/or function of these transcription factors, or of the c-Myc and Max interacting proteins, such as MM-1 and Mxi1, can influence the neoplastic process. Understanding how c-Myc controls cellular phenotypes, including the leukemic phenotype, should provide novel tools for designing drugs to promote differentiation and/or apoptosis of leukemic cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S . 1999 Oncogene 18: 5268–5277
Alland L, Muhle R, Hou Jr H, Potes J, Chin L, Schreiber-Agur N, DePinho RA . 1997 Nature 387: 49–55
Amanullah A, Liebermann DA, Hoffman B . 2000 Oncogene 19: 2967–2977
Amanullah A, Liebermann DA, Hoffman B . 2002 Oncogene 21: 1600–1610
Amati B, Land H . 1994 Curr. Opin. Genet. Dev. 4: 102–108
Askew DS, Ashmun RA, Simmons BC, Cleveland JL . 1991 Oncogene 6: 1915–1922
Ayer DE, Eisenman N . 1993 Genes Dev. 7: 2110–2119
Ayer DE, Kretzner L, Eisenman RN . 1993 Cell 72: 211–222
Ayer DE, Lawrence QA, Eisenman RN . 1995 Cell 80: 767–776
Baudino TA, Cleveland JL . 2001 Mol. Cell. Biol. 21: 691–702
Beckmann AM, Wilce PA . 1997 Neurochem. Int. 4: 477–510
Beijersbergen RL, Hijmans EM, Zhu L, Bernards R . 1994 EMBO J. 13: 4080–4086
Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Macgrath I . 1993 Nat. Genet. 5: 56–61
Bhatia K, Spangler G, Hamdy N, Neri A, Brubaker G, Levin A, Macgrath I . 1995 Curr. Top. Microbiol. Immunol. 194: 389–398
Bissonnette RP, Echeverri F, Mahboubi A, Green DR . 1992 Nature 359: 552–554
Blackwell TK, Kretzner L, Backwood EM, Eisenman RN, Weintraub H . 1990 Science 250: 1149–1151
Boxer LM, Dang CV . 2001 Oncogene 20: 5595–5610
Brunner T, Kasibhatla S, Pinkoski MJ, Frutschi C, Yoo NJ, Echeverri F, Mahboubi A, Green DR . 2000 J. Biol. Chem. 275: 9767–9772
Cambier N, Zhang Y, Vairo G, Kosmopoulos K, Metcalf D, Nicola NA, Elefanty AG . 1999 Oncogene 18: 343–352
Cameron ER, Morton J, Johnston CJ, Irvine J, Bell M, Onions DE, Neil JC, Campbell M, Blyth K . 2000 Cell Death Differ. 7: 80–88
Chang DH, Angelin-Duclos C, Calame K . 2000 Nat. Immunol. 1: 169–176
Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD . 1995 Nat. Med. 1: 638–643
Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB . 2000 J. Biol. Chem. 275: 32227–32233
Claassen GF, Hann SR . 1999 Oncogene 18: 2925–2933
Crossen PE, Savage LM, Heaton DC, Morrison MJ . 1999 Cancer Genet. Cytogenet. 112: 144–148
Cultraro CM, Bino T, Segal S . 1997 Mol. Cell. Biol. 17: 2353–2359
Dang CV . 1999 Mol. Cell. Biol. 19: 1–11
Davies J, Badiani P, Weston K . 1999 Oncogene 18: 3643–3647
Delgardo MD, Chernukhin IV, Bigas A, Klenova EM, Leon J . 1999 FEBS Lett. 444: 5–10
Eischen CM, Woo D, Roussel MF, Cleveland JL . 2001 Mol. Cell. Biol. 21: 5063–5070
Elliott K, Ge K, Du W, Prendergast GC . 2000 Oncogene 19: 4669–4684
Evan GI, Littlewood TD . 1993 Curr. Opin. Genet. Dev. 3: 44–49
Fanidi A, Harrington EA, Evan GI . 1992 Nature 359: 554–556
Fecho K, Bentley SA, Cohen PL . 1998 Cell Immunol. 188: 19–32
Feinberg A . 2001 Proc. Natl. Acad. Sci. USA 98: 392–394
Felsher DW, Bishop JM . 1999a Proc. Natl. Acad. Sci. USA 96: 3940–3944
Felsher DW, Bishop JM . 1999b Mol. Cell 4: 199–207
Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN . 1998 EMBO J. 17: 774–785
Freytag SO . 1988 Mol. Cell. Biol. 8: 1614–1624
Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, Nagashima K, Ariga H . 2001 J. Biol. Chem. 276: 45137–45144
Genestier L, Kasibhatla S, Brunner T, Green DR . 1999 J. Exp. Med. 189: 231–239
Gu W, Bhatia K, MacGrath IT, Dang CV, Dalla-Favera R . 1994 Science 264: 251–254
Harper SE, Qiu Y, Sharp PA . 1996 Proc. Natl. Acad. Sci. USA 93: 8536–8540
Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE . 1997 Cell 89: 341–347
Haupt Y, Harris AW, Adams JM . 1993 Int. J. Cancer 55: 623–629
Henriksson M, Luscher G . 1996 Adv. Cancer Res. 68: 110–182
Hoffman B, Liebermann DA . 1998 Oncogene 17: 3351–3357
Hoffman B, Liebermann DA, Selvakumaran M, Nguyen HQ . 1996 Curr. Top. Microbiol. Immunol. 211: 17–27
Hoffman-Liebermann B, Liebermann DA . 1991 Mol. Cell. Biol. 11: 2375–2381
Hurlin PJ, Queva C, Koshinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN . 1995 EMBO J. 14: 5646–5659
Hurlin PJ, Queva C, Eisenman RN . 1997 Genes Dev. 11: 44–58
Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG . 2001 Mol. Cell. Biol. 21: 3789–3806
Koshinen PJ, Ayer DE, Eisenman RN . 1995 Cell Growth Differ. 6: 623–629
Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B . 1995 Mol. Cell. Biol. 15: 5499–5507
Krishnaraju K, Hoffman B, Liebermann DA . 1998 Blood 92: 1957–1966
Krishnaraju K, Hoffman B, Liebermann DA . 2001 Blood 97: 1298–1305
Laherty D, Yang W, Sun J, Davie JR, Seto E, Eisenman RN . 1997 Cell 89: 349–356
Lahox EG, Xu L, Schreiber-Agus N, DePinho RA . 1994 Proc. Natl. Acad. Sci. USA 91: 5503–5507
Landshulz WH, Johnson PF, McKnight SL . 1988 Science 240: 1759–1764
Li LH, Nerlov C, Prendergast G, McGregor D, Ziff EB . 1994 EMBO J. 13: 4070–4079
Liebermann DA, Gregory B, Hoffman B . 1998 Int. J. Onc. 12: 685–700
Lindeman GJ, Harris AW, Bath ML, Eisenman RN, Adams JM . 1995 Oncogene 10: 1013–1017
Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA . 1993 Mol. Cell. Biol. 13: 841–851
McKenna SL, Cotter TG . 1997 Adv. Cancer Res. 71: 121–164
McMahon SB, Monroe JG . 1996 J. Leukoc. Biol. 2: 159–166
McMahon SB, Wood MA, Cole MD . 2000 Mol. Cell. Biol. 20: 556–562
Metcalf D . 1989 Nature 339: 27–30
Metcalf D . 1991 Science 254: 529–533
Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SMM, Ariga H . 1998 J. Biol. Chem. 273: 29794–29800
Murre C, Schonleber-McCaw P, Baltimore D . 1989 Cell 56: 777–783
Nesbit CE, Tersak JM, Prochownik EV . 1999 Oncogene 18: 3004–3016
Nguyen H, Hoffman-Liebermann B, Liebermann DA . 1993 Cell 72: 197–209
O'Malley F, Rayeroux K, Cole-Sinclair M, Tong M, Campbell LJ . 1999 Cancer Genet. Cytogenet. 109: 123–125
Ohlsson R, Renkawitz R, Lobanenkov V . 2001 Trends Genet. 17: 520–527
Packham G, Cleveland JL . 1995 Biochim. Biophys. Acta 1242: 11–28
Quesenberry PJ . 1990 Hematology, Williams WJ, Beutler E, Erslev AJ and Lichtman MA (eds) New York: McGraw-Hill pp 129–147
Rabbitts TH, Hamlyn PH, Baer R . 1983 Nature 306: 760–765
Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA . 1996 Oncogene 12: 1165–1172
Rasko JE, Klenova EM, Leon J, Filippova GN, Loukinov DI, Vatolin S, Robinson AF, Hu YJ, Ulmer J, Ward MD, Pugacheva EM, Neiman PE, Morse III HC, Collins SJ, Lobanenkov VV . 2001 Cancer Res. 61: 6002–6007
Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE . 1996 Mol. Cell. Biol. 16: 2796–2801
Ryan KM, Birnie GD . 1997 Oncogene 14: 2835–2843
Sachs L . 1987 Science 238: 1374–1379
Sakamuro D, Prendergast GC . 1999 Oncogene 18: 2942–2954
Schmidt M, Nazarov V, Stevens L, Watson R, Wolff L . 2000 Mol. Cell. Biol. 20: 1970–1981
Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi A, DePinho RA . 1995 Cell 80: 777–786
Schreiber-Agus N, Meng Y, Hoang T, Hou Jr J, Chen K, Greenberg R, Cordon-Cardo C, Lee H-W, DePinho RA . 1998 Nature 393: 483–487
Selvakumaran M, Lin HK, TjinThamSjin R, Reed JC, Liebermann DA, Hoffman B . 1994 Mol. Cell. Biol. 14: 2352–2360
Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . 1992 Science 257: 212–214
Strasser A, Harris AW, Bath ML, Cory S . 1990 Nature 348: 331–333
Traver D, Akashi K, Weissman IL, Lagasse E . 1998 Immunity 9: 47–57
Wu SJ, Pena A, Korcz A, Soprano DR, Soprano KJ . 1996 Oncogene 12: 621–629
Zervos AS, Gyuris J, Brent R . 1993 Cell 72: 223–232
Zhang D-E, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG . 1997 Proc. Natl. Acad. Sci. USA 94: 569–574
Zornig M, Grzeschiczek A, Kowalski M-B, Hartmann K-U, Moroy T . 1995 Oncogene 10: 2397–2401
Acknowledgements
This research was supported by National Institute of Health Grant RO1 CA81168 (to B Hoffman).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoffman, B., Amanullah, A., Shafarenko, M. et al. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21, 3414–3421 (2002). https://doi.org/10.1038/sj.onc.1205400
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205400